Latest from Sarah Cannon

Suman Kambhampati, MD, discusses some of the latest developments in the treatment of patients with relapsed/refractory multiple myeloma.

Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses the CAPTIVATE trial in patients with chronic lymphocytic leukemia (CLL).

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses breast cancer data presented at the 2018 ASCO Annual Meeting.
 

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the role of biosimilars in the treatment of patients with breast cancer.
 

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer. 

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses Hu5F9-G4 (5F9) plus rituximab (Rituxan) in patients with non-Hodgkin lymphoma.
 

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).